SWEET

  • Research type

    Research Study

  • Full title

    Supporting Women with adhErence to adjuvant Endocrine Therapy following breast cancer (SWEET)

  • IRAS ID

    293238

  • Contact name

    Linda Sharp

  • Contact email

    linda.sharp@ncl.ac.uk

  • Sponsor organisation

    Newcastle upon Tyne Hospitals NHS Foundation Trust

  • Duration of Study in the UK

    0 years, 7 months, 31 days

  • Research summary

    In 2016, 11,563 women died from breast cancer in the UK. Most would have been prescribed endocrine therapy (ET); sometimes known as hormone therapy, which blocks the effect of oestrogen on breast cancer cells. ET is prescribed as a daily tablet, usually for at least five years. When women stop taking ET prematurely, or don’t take it as prescribed (known as “poor adherence”), they have up to a three times higher chance of the cancer returning and dying from cancer. At least 20% of women have poor adherence after two years and around 50% by five years.

    Our previous research has identified reasons for poor adherence, including: feeling negative or concerned about ET; not fully understanding its importance; side-effects; feeling unsupported; and forgetfulness.

    SWEET is an NIHR funded a research programme, which supported by a User Advisory Group, will develop and test a support package to support women take ET as recommended. SWEET will be delivered over 6 workstreams.

    This application refers to the first workstream of the SWEET research programme. Stakeholder consultation and patient and public involvement has contributed to the development of a prototype digital component (web-based application that can be accessed via a smartphone, tablet or computer).

    Using qualitative methods, we will take two complementary approaches (sub-studies) to user pre-testing to provide different insights into the usability of the digital component of the prototype intervention. The first sub-study aims to conduct usability testing to explore women’s immediate and observable reactions to, and views and experiences of, using the digital component. The second sub-study aims to conduct pre-testing to explore women’s views and experiences of using the digital component in a real-life context.

    Together these sub-studies will help to help to identify problems and inform changes to the details, layout, format, content and processes of the digital component.

  • REC name

    London - Central Research Ethics Committee

  • REC reference

    21/PR/0603

  • Date of REC Opinion

    7 Jun 2021

  • REC opinion

    Favourable Opinion